459 related articles for article (PubMed ID: 26337218)
1. Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics.
You Tm; Lee KH; Lee SH; Park W
Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Nov; 120(5):548-53. PubMed ID: 26337218
[TBL] [Abstract][Full Text] [Related]
2. [Bisphosphonate and denosumab-related osteonecrosis of the jaw: Epidemiology, diagnosis and management].
Dupic G; Collangettes D; Dillies AF; Calvet L; Tournilhac O; Bay JO; Mahammedi H
Bull Cancer; 2015 Dec; 102(12):1010-9. PubMed ID: 26607453
[TBL] [Abstract][Full Text] [Related]
3. Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis.
Voss PJ; Steybe D; Poxleitner P; Schmelzeisen R; Munzenmayer C; Fuellgraf H; Stricker A; Semper-Hogg W
Odontology; 2018 Oct; 106(4):469-480. PubMed ID: 29713913
[TBL] [Abstract][Full Text] [Related]
4. Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review.
de Oliveira CC; Brizeno LA; de Sousa FB; Mota MR; Alves AP
Med Oral Patol Oral Cir Bucal; 2016 Jul; 21(4):e431-9. PubMed ID: 26827069
[TBL] [Abstract][Full Text] [Related]
5. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
[TBL] [Abstract][Full Text] [Related]
6. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
[TBL] [Abstract][Full Text] [Related]
7. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.
Khan AA; Morrison A; Kendler DL; Rizzoli R; Hanley DA; Felsenberg D; McCauley LK; O'Ryan F; Reid IR; Ruggiero SL; Taguchi A; Tetradis S; Watts NB; Brandi ML; Peters E; Guise T; Eastell R; Cheung AM; Morin SN; Masri B; Cooper C; Morgan SL; Obermayer-Pietsch B; Langdahl BL; Dabagh RA; Davison KS; Sándor GK; Josse RG; Bhandari M; El Rabbany M; Pierroz DD; Sulimani R; Saunders DP; Brown JP; Compston J;
J Clin Densitom; 2017; 20(1):8-24. PubMed ID: 27956123
[TBL] [Abstract][Full Text] [Related]
8. Antiresorptive drug-related osteonecrosis of the jaw.
Uyanne J; Calhoun CC; Le AD
Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced osteonecrosis of the jaw: the state of the art.
Fassio A; Bertoldo F; Idolazzi L; Viapiana O; Rossini M; Gatti D
Reumatismo; 2017 May; 69(1):9-15. PubMed ID: 28535616
[TBL] [Abstract][Full Text] [Related]
10. Antiresorptive treatment-associated ONJ.
Eleutherakis-Papaiakovou E; Bamias A
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 29063702
[TBL] [Abstract][Full Text] [Related]
11. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
Dodson TB
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
[TBL] [Abstract][Full Text] [Related]
12. Healing of osteonecrosis of the jaw (ONJ) after discontinuation of denosumab in a patient with bone metastases of colorectal cancer: a case report and hypothesis.
Ohga N; Yamazaki Y; Tsuboi K; Kitagawa Y
Quintessence Int; 2015; 46(7):621-6. PubMed ID: 25646168
[TBL] [Abstract][Full Text] [Related]
13. Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series.
Aljohani S; Gaudin R; Weiser J; Tröltzsch M; Ehrenfeld M; Kaeppler G; Smeets R; Otto S
J Craniomaxillofac Surg; 2018 Sep; 46(9):1515-1525. PubMed ID: 29983309
[TBL] [Abstract][Full Text] [Related]
14. Denosumab-related osteonecrosis of the jaw: a report of 2 cases and review of the literature.
Chehal H; Nikitakis NG; Islam MN; Goodchild JH; Mordini L; Bhattacharyya I
Gen Dent; 2019; 67(1):42-46. PubMed ID: 30644830
[TBL] [Abstract][Full Text] [Related]
15. Update MRONJ and perspectives of its treatment.
Voss PJ; Poxleitner P; Schmelzeisen R; Stricker A; Semper-Hogg W
J Stomatol Oral Maxillofac Surg; 2017 Sep; 118(4):232-235. PubMed ID: 28697987
[TBL] [Abstract][Full Text] [Related]
16. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
[TBL] [Abstract][Full Text] [Related]
17. [Current situation and future issues of antiresorptive agent-related osteonecrosis of the jaw].
Takaoka K; Kishimoto H
Nihon Yakurigaku Zasshi; 2019; 153(1):22-27. PubMed ID: 30643088
[TBL] [Abstract][Full Text] [Related]
18. Denosumab-related osteonecrosis of the jaws: successful management with a conservative surgical approach.
de Souza Póvoa RC; Marlierè DA; da Silveira HM; Pires FR
Spec Care Dentist; 2016 Jul; 36(4):231-6. PubMed ID: 26859582
[TBL] [Abstract][Full Text] [Related]
19. Management of Medication-Related Osteonecrosis of the Jaw.
Williams WB; O'Ryan F
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):517-25. PubMed ID: 26515735
[TBL] [Abstract][Full Text] [Related]
20. Denosumab-related osteonecrosis of the jaw following non-surgical periodontal therapy: A case report.
Diniz-Freitas M; Fernández-Feijoo J; Diz Dios P; Pousa X; Limeres J
J Clin Periodontol; 2018 May; 45(5):570-577. PubMed ID: 29479739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
